Navigation Links
Sixty Percent of Surveyed Type 2 Diabetes Patients in the U.S. Who Use Insulin Indicate They Would Request a Switch to a Less Expensive Biosimilar Insulin if Such an Agent Became Available
Date:12/23/2010

BURLINGTON, Mass., Dec. 23, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

The new Patient Forum report entitled Patient Forum in Type 2 Diabetes: Patients' resistance to injectable agents may cause challenges for emerging GLP-1 analogues finds that although most surveyed type 2 diabetes patients indicate that they have some form of prescription coverage associated with their insurance, patients taking insulin report that they feel their disease is a greater financial burden compared to other patient segments. The majority of surveyed insulin users indicate they are also taking at least one oral antidiabetic, resulting in multiple copayments each month, increasing the monthly out-of-pocket cost for these patients.

"In addition, since patients who take insulin are generally advised to check their blood glucose at least twice each day, the cost of the necessary equipment such as test strips and glucose meters also contributes to a greater financial burden for insulin patients," said Decision Resources Program Manager Jennifer Moniz Carpenter, M.B.A.

Surveyed users of Amylin/Eli Lilly's Byetta are the most likely to request a switch to an agent that is injected once a week or once a month, suggesting that these patients may request a switch to an emerging GLP-1 analogue with improved dosing if they become aware of the drug.

"Amylin and Eli Lilly may be able to avoid loss of sales to other emerging GLP-1 analogues by campaigning for physicians to switch current Byetta users to the extended-release formulation, Bydureon, when the drug becomes available," Ms. Moniz Carpenter said.

About Decision Resour
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
4. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
5. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
6. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
7. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)
8. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
9. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
10. A Drug With Efficacy Superior to That of Xenical at Inducing Weight Loss Would Earn a 40 Percent Patient Share in the Obesity Drug Market
11. CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
(Date:9/23/2014)... World of Home Fitness is committed to supporting ... gym has been raising money to support Meals on ... World of Home Fitness has participated in and raised ... summer, World of Home Fitness raised more than $600 ... participants helped feed seniors "one rep at a time." ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows ... how it can be treated. , A medically retired ... 2006. His platoon sustained multiple attacks resulting in five ... with combat-related PTSD and honorably discharged from the Army. ... had distanced myself from my friends and family,” recalled ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
(Date:9/23/2014)... As a consumer in today’s world, ... It’s difficult to trust testimonials that are supplied by ... manipulate their customers into saying anything. , Consumer advocacy ... to lack in depth coverage on a particular market ... to fix this issue and focus on exposing the ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 Dr. Connie ... her medical practices to new office space at 12200 Park ... Located at the office will be Park Cities Aesthetics, Optimal ... , In announcing her move, Dr. Casad said, “The ... what treatment they select, we want them to always feel ...
Breaking Medicine News(10 mins):Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Dr. Connie Casad Moving to New Office Location 2
... BIRMINGHAM, Ala. Leading high-performance computing engineers and ... University of Alabama at Birmingham (UAB) have called ... group says growing world-wide computer use puts more ... projects that are stored digitally at risk for ...
... lanes could protect more riders, researchers say , WEDNESDAY, Oct. ... and longer hospital stays, with both worsening over the past ... results of a study of biking injuries. , Chest injuries ... last five years, the study authors found. Cyclists themselves appear ...
... , MENLO PARK, Calif., Oct. 14 New Enterprise Associates, ... that Ravi Viswanathan, PhD, has been promoted to General Partner. ... on energy and growth equity information technology investments, as well ... Frank Torti, MD, to Principal. Dr. Torti joined NEA in ...
... ... industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) ... ... a global health care company in the emerging medical tourism industry, announced the addition of ...
... As the leaves begin to change color and ... today announced the launch of "A BETTER BEDTIME," its 2009-2010 ... campaign is based online at the Official Pajama Program A ... , Pajama Program provides new pajamas and new books to ...
... a third of deaths, study finds, , WEDNESDAY, Oct. 14 (HealthDay ... who share a bed or sofa with a parent, and alcohol ... many of the cases, says a U.K. study. , Researchers analyzed ... between January 2003 and December 2006. Of the deaths, 54 percent ...
Cached Medicine News:Health News:UAB international conference focuses on preventing high-capacity computer data theft 2Health News:As More Cyclists Hit the Road, Serious Injuries Rise 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 3Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 4Health News:Shared Bed May Raise SIDS Risk 2
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: